RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties

← Drug Reference

Allopurinol

management of primary or secondary gout, management of leukemia, lymphoma and solid tumor malignancies, management of recurrent calcium oxalate calculi

Indications

  • management of primary or secondary gout
  • management of leukemia, lymphoma and solid tumor malignancies
  • management of recurrent calcium oxalate calculi

Adult dosing

  • gout initial: dose: 100; unit: mg; route: PO; interval: daily, increase by 100 mg weekly increments (max 800 mg daily); fixed: true; labelExcerpt: Patients with normal kidney function: Initial dosage is 100 mg orally daily. Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maximum 800 mg daily).
  • cancer therapy: dose: 300; unit: mg; route: PO; interval: daily (300 mg to 800 mg); fixed: true; labelExcerpt: Adult patients – 300 mg to 800 mg orally daily
  • calcium oxalate calculi: dose: 200; unit: mg; route: PO; interval: daily (200 mg to 300 mg); fixed: true; labelExcerpt: The recommended initial dosage in patients with normal kidney function is 200 mg to 300 mg orally daily.

Pediatric dosing

  • cancer therapy: dose: 10; unit: mg/kg/day; route: PO; interval: daily total divided every 8-12 hours (not per dose); weightBased: true; maxDose: 800; maxDoseAbsolute: true; labelExcerpt: Pediatric patients: 100 mg/m 2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day)

Renal adjustment

  • Consult pharmacy/current label

Hepatic adjustment

  • Consult pharmacy/current label

Contraindications

  • hypersensitivity to allopurinol

Clinical pearls

  • Discontinue immediately if skin rash occurs as it may signify severe hypersensitivity like SJS/TEN.
  • Initiate prophylaxis with colchicine or anti-inflammatory agents to prevent gout flares.
  • Maintain adequate fluid intake (at least 2 liters/day) to prevent kidney stone formation.
  • Monitor renal function during the early stages of treatment.

Source and review

  • DailyMed label (allopurinol), Set ID 156d743c-6324-44db-9230-21f762d64cfd, effective 2026-11-04. Last reviewed: 2026-11-11